Skip to content
Screener

Operating Income at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$1.29B+19.8%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-$75M+30.6%
uniQure logo
uniQureQURE
-$52.2M-19.0%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$44.96M-95.4%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-$126.27M-18.3%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$2.41M+614%

Segments

By segment

See full
Therapeutics Segment-$130.54M+3.3%

Other financials

Income statement

See full
Revenue$3.6M
Gross profit$3.5M
Net income-$127.6M-2.8%
EPS (diluted)-$0.68+5.6%

Balance sheet

See full
Cash & equivalents$204.6M+41.8%
Total debt$37.7M-21.4%
Total equity$835.2M-18.7%
Total assets$1.2B-0.7%

Cash flow

See full
Operating cash flow-$97.0M-28.8%
CapEx$805.0K-81.2%
Free cash flow-$97.8M-22.9%

Valuation

See full
Market cap$3.92B+88.3%
Enterprise value$3.76B+89.0%
P/S1,089×+1,084×

Profitability

See full
Operating margin-37,938%-37,986pp
Net margin-33,121.9%-33,159pp
FCF margin-31,736.3%-31,830pp

Returns & leverage

See full
Return on equity-54.9%+34.3pp
Debt / equity0.0×
Current ratio8.4×-1.9×

Where this comes from

Reported directly by Denali Therapeutics Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: Denali Therapeutics Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:08 PM EDT
Fiscal quarter
Q4 FY2026
Calendar quarter
Q4 2026
Accession
0001714899-26-000097
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Selling, general and administrative36,28332,26769,79461,620
Intangible asset amortization750750
Total operating expenses134,145134,963271,502280,543
Loss from operations(130,541)(134,963)(267,898)(280,543)
Interest and other income, net2,98810,84411,89823,454
Net loss$(127,553)$(124,119)$(256,000)$(257,089)
Other comprehensive loss:
Net unrealized loss on marketable securities, net of tax(1,287)(1,098)(2,651)(1,081)

Item 1. Financial Statements (Unaudited)

FAQ

What is Denali Therapeutics Inc.'s operating income?
Denali Therapeutics Inc. (DNLI) reported operating income of -$130.54M in Q2 2026.
How has Denali Therapeutics Inc.'s operating income changed year-over-year?
Denali Therapeutics Inc.'s operating income increased by 3.3% year-over-year, from -$134.96M to -$130.54M.
What is the long-term trend for Denali Therapeutics Inc.'s operating income?
Over 4 years (2021 to 2025), Denali Therapeutics Inc.'s operating income has grown at a 17.1% compound annual growth rate (CAGR), from -$295.75M to -$555.34M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.

Ask your AI about Denali Therapeutics Inc.'s operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude